Featured
Oct 16 | First clinical test of RNA editing restores missing protein in genetic disease, Wave says read more » |
Oct 16 | Gene Therapy Automatically Converts Omega-6 to Omega-3 Fatty Acids in the Body read more » |
Oct 15 | On Heels of Positive Parkinson's Gene Therapy Data, MeiraGTx Looks Ahead to Pivotal Test read more » |
Oct 16 | Study explores how traumatic brain injury may be linked to Alzheimer's disease read more » |
Oct 16 | Gene editing approach helps launch first-in-human clinical trial for rare genetic disease read more » |
Oct 16 | ARTHEx Biotech Announces Publication of Promising Preclinical Research for Myotonic Dystrophy Type 1 (DM1) read more » |
Oct 15 | GSK sues Moderna over mRNA vaccine patents, seeks 'reasonable royalty' read more » |
Oct 14 | Improving the recipe for gene therapy: New treatment for Gaucher disease shows promise read more » |
Oct 10 | Diverse Genomes Make Medicine More Equitable read more » |
Oct 16 | Suppression of CNS APOE4 Expression by miRNAs Delivered by the S2 AAVrh.10 Capsid-Modified AAV Vector read more » |
Oct 16 | Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR–Cas9 ribonucleoprotein read more » |
Oct 11 | Model-directed generation of artificial CRISPR–Cas13a guide RNA sequences improves nucleic acid detection read more » |
Oct 08 | Systemic gene therapy corrects the neurological phenotype in a mouse model of NGLY1 deficiency read more » |
Oct 01 | Multi-species genome-wide CRISPR screens identify conserved suppressors of cold-induced cell death read more » |
PackGene’s Newsletter
Receive the latest news and insights to your inbox.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE